1-9 of 9
Ling Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates

Free
Yuhong Ren, Jing Li, Zhixiang Cheng, Jingli Zhuang, Hui Tan, Luya Cheng, Ling Yuan, Yang Ke, Peng Liu
Journal: Blood
Blood (2025) 146 (Supplement 1): 1917.
https://doi.org/10.1182/blood-2025-1917
Published: 2025
Journal Articles

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma

Free
Yuhong Ren, Yang Ke, Zhixiang Cheng, Ling Yuan, Weiguang Wang, Jingli Zhuang, Luya Cheng, Yue Wang, Jiadai Xu, Xuejiao Zhang, Jing Li, Peng Liu
Journal: Blood
Blood (2025) 146 (Supplement 1): 7257.
https://doi.org/10.1182/blood-2025-7257
Published: 2025
Journal Articles

Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq

Free
Shuhui Yu, Yueqiang Wang, Wenxin Zhu, Qin Chen, Biao Wang, Qiang Wu, Yali Zhou, Ling Yuan, Sha Li, Xiaojing Zhang, Mingxi Chen, Mengyao Wang, Liping Zhu, Yajin Ni, Jan Davidson-Moncada, Jiangtao Ren
Journal: Blood
Blood (2025) 146 (Supplement 1): 4122.
https://doi.org/10.1182/blood-2025-4122
Published: 2025
Journal Articles

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Free
Yian Zhang, Ling Yuan, Jingli Zhuang, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Peng Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6304.
https://doi.org/10.1182/blood-2023-185411
Published: 2023
Journal Articles

Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

Free
Yuhong Ren, Jingli Zhuang, Ling Yuan, Lili Ji, Yang Ke, Peng Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1747.
https://doi.org/10.1182/blood-2023-186170
Published: 2023
Journal Articles

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Free
Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, PhD, Ling-Yuan Kong, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, David Maxwell, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD
Journal: Blood
Blood (2007) 110 (11): 1556.
https://doi.org/10.1182/blood.V110.11.1556.1556
Published: 2007
Journal Articles

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Free
Geoffrey A. Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, Ling Yuan Kong, Shimei Wang, Zeev Estrov, Waldemar Priebe, Ji Wu, Nicholas J. Donato
Journal: Blood
Blood (2007) 109 (8): 3470–3478.
https://doi.org/10.1182/blood-2006-02-005579
Published: 2007
Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Free
Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2005) 106 (11): 1087.
https://doi.org/10.1182/blood.V106.11.1087.1087
Published: 2005
Journal Articles

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Free
Ling-Yuan Kong, MD, PhD, Vaibhav Kapuria, Geoffrey Bartholomeusz, PhD, Moshe Talpaz, MD, Waldemar Priebe, PhD, Nicholas J. Donato, PhD
Journal: Blood
Blood (2005) 106 (11): 1489.
https://doi.org/10.1182/blood.V106.11.1489.1489
Published: 2005